- Approval Id
- 9c7e024f1656cc1c
- Drug Name
- TIDACT INJECTION 150 mg/ml
- Product Name
- TIDACT INJECTION 150 mg/ml
- Approval Number
- SIN07759P
- Approval Date
- 1994-07-01
- Registrant
- YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
- Licence Holder
- YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- INJECTION
- Dosage
- **Dosage and Administration:**
Single I.M. injection should not exceed 600mg; for I.V. infusion, do not administer more than 1200mg in a single 1 hour infusion.
Adult dose: I.M. or I.V.
Ordinary infections: 600–1200mg/day in 2,3 or 4 equal doses.
Serious infections: 1200–1800mg/day in 3 or 4 equal doses.
Very serious infections: 2400–2700mg/day in 2,3 or 4 equal doses.
In life threatening situations, a maximum of 4800mg/day may be given I.V.
May be administered as a single rapid infusion on the first dose and followed by continuous I.V. infusion, as follows:
To maintain serum
To prepare initial dilution for I.V. dose, each dose must be diluted as follows (it must not be administered undiluted as a bolus):
Children dose: I.M. or I.V.
Infants up to 1 month of age: 15–20mg/kg/day in 3 or 4 equal doses.
Over 1 month of age: 20–40mg/kg/day in 3 or 4 equal doses.
May be given based on body surface area:
Serious infections: 350mg/m2/day
More serious infections: 450mg/m2/day
In _β_-hemolytic streptococcal infection, treatment should be continued for at least 10 days.
To be administered only by a physician.
- Route Of Administration
- INTRAVENOUS, INTRAMUSCULAR
- Indication Info
- **Indications:**
For the treatment of serious infections due to susceptible strains of Staphylococci, Streptococci, Pneumococci, and anaerobic bacteria.
- Contraindications
- **Contraindications:**
1. History of gastrointestinal disease, especially ulcerative colitis, regional enteritis, and antibiotic-associated colitis. Clindamycin may cause pseudomembranous colitis.
2. Severe hepatic function impairment. Half-life of Clindamycin is prolonged in this condition, therefore may require dosage adjustment.
3. Hypersensitivity to Lincomycins and doxorubicin.
4. Severe renal function impairment may require reduction of dosage.
- Atc Code
- J01FF01
- Atc Item Name
- clindamycin
- Pharma Manufacturer Name
- YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
- Company Detail Path
- /organization/yung-shin-pharmaceutical-singapore-pte-ltd
